Metastatic Breast Cancer: Overview of Treatment

Clinical Orthopaedics and Related Research

Volumn 415, Issue SUPPL., 2003, Pages

  Ali, Suhail M ^a,b,c   Harvey, H A ^a   Lipton, Allan ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; ANTIMETABOLITE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; FOLINIC ACID; FULVESTRANT; LETROZOLE; MEGESTROL ACETATE; MITOXANTRONE; NAVELBINE; PACLITAXEL; PAMIDRONIC ACID; TAMOXIFEN; TAXANE DERIVATIVE; TOREMIFENE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; ZOLEDRONIC ACID;

BODY BURDEN; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FUNCTIONAL ASSESSMENT; HUMAN; METASTASTIC BREAST CANCER; ONCOGENE NEU; OVARIECTOMY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SYMPTOM; SYMPTOM CONTROL; TUMOR VOLUME;

EID: 0142157076     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/01.blo.0000092981.12414.7b     Document Type: Conference Paper

References (22)

1. Alexandre J, Bleuzen P, Bonneterre J, et al: Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 18:562-573, 2000.
2. Ali SM, Leitzel K, Chinchilli VM, et al: Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem 48:1314-1320, 2002.
3. Buzdar A, Jonat W, Howell A, et al: Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials: Arimidex Study Group. J Clin Oncol 14:2000-2011, 1996.
4. Buzdar A, Douma J, Davidson N, et al: Phase III, multicenter, double blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 19: 3357-3366, 2001.
5. Coleman RE: Efficacy of zoledronic acid and pamidronate in breast cancer patients: A comparative analysis of randomized phase III trials. Am J Clin Oncol 6(Suppl 1):S25-31, 2002.
6. Coleman RE, Rubens RD: The clinical course of bone metastases from breast cancer. Br J Cancer 55: 61-66, 1987.
7. Coleman RE, Rubens RD: The clinical course of bone metastasis and prognostic factors following recurrence from breast cancer. Br J Cancer 77:336-340, 1998.
8. Del Mastro L, Venturini M, Lionetto R, et al: Accelerated-Intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: Results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group. J Clin Oncol 19:2213-2221, 2001.
9. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998.
10. Hortobagyi GN, Theriault RL, Lipton A, et al: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate: Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16: 2038-2044, 1998.
11. Jacobson AF, Shapiro CL, Van den Abbeele AD, et al: Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma. Cancer 91:17-24, 2001.
12. Jassem J, Pienkowski T, Pluzanska A, et al: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial. J Clin Oncol 19:1707-1715, 2001.
13. Lipton A, Ali SM, Leitzel K, et al: Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20:1467-1472, 2002.
14. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the Intemational Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2002.
15. Nabholtz JM, Falkson C, Campos D, et al: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. J Clin Oncol 21: 968-975, 2003.
16. Rosen LS, Gordon D, Kaminski M, et al: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 7:377-387, 2001.
17. Slamon DJ, Clark GM, Wong SG, et al: Breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
18. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001.
19. Sledge GW, Neuberg D, Bernardo P, et al: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). J Clin Oncol 21:588-592, 2003.
20. Theriault RL, Lipton A, Hortobagyi GN, et al: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial: Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17: 846-854, 1999.
21. Valero V, Hortobagyi GN: Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? J Clin Oncol 21:959-962, 2003.
22. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002.